Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identifying outcome measures for clinical trials in juvenile idiopathic arthritis associated uveitis for the MIWGUC proposal: a scoping review to create domains from existing outcome measures.

Pediatric rheumatology online journal·2026
Same author

Are we ready to predict progressive disease in juvenile systemic sclerosis?

Journal of scleroderma and related disorders·2026
Same author

What is the treatment pattern of juvenile systemic sclerosis? Results from an international cohort.

Journal of scleroderma and related disorders·2026
Same author

Measuring disease activity in juvenile systemic sclerosis: a multidisciplinary consensus from the Hamburg 2024 symposium.

Expert review of clinical immunology·2026
Same author

Serological biomarkers of JIA-associated uveitis: ANA titers, ANA AC-30 staining pattern and prefoldin 5 antibodies.

Arthritis research & therapy·2026
Same author

What is the best way to plan a 12-month clinical drug trial in JIA associated uveitis?

Expert review of clinical immunology·2026
Same journal

Intensive Care Management of ANCA-associated Vasculitides: a Narrative Review.

Current rheumatology reports·2026
Same journal

The Role of Musculoskeletal Ultrasound in Psoriatic Arthritis: From Preclinical Detection to Treatment Monitoring.

Current rheumatology reports·2026
Same journal

Correction to: Is Gout and Autoinflammatory Disease?

Current rheumatology reports·2026
Same journal

Risks and Management of Glucocorticoid Therapy for Patients with Rheumatic Disease Having Surgery.

Current rheumatology reports·2026
Same journal

Perioperative Management Considerations for Patients with Systemic Lupus Erythematosus.

Current rheumatology reports·2026
Same journal

Management of IgG4-Related Disease.

Current rheumatology reports·2026
See all related articles

Related Experiment Video

Updated: Jun 24, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Current developments in pediatric systemic sclerosis.

Ivan Foeldvari1

  • 1Hamburger Zentrum für Kinder- und Jugendrheumatologie, Kompetenz-Zentrum für Sklerodermie und autoimmune Uveitis im Kindesalter, Am Klinikum Eilbek, Dehnhaide 120, D-22081, Hamburg, Germany. sprechstunde@kinderrheumatologie.de

Current Rheumatology Reports
|March 20, 2009
PubMed
Summary
This summary is machine-generated.

Juvenile systemic sclerosis, a rare childhood disease, presents differently than in adults, with distinct organ involvement and better survival rates. Disease subsets also shift over time, impacting long-term outcomes.

Related Experiment Videos

Last Updated: Jun 24, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Area of Science:

  • Rheumatology
  • Pediatric autoimmune diseases
  • Rare diseases

Background:

  • Juvenile systemic sclerosis (JSSc) is a rare autoimmune condition affecting children.
  • It has an incidence of approximately 0.05 per 100,000 children, with a mean age of onset around 8 years.
  • The diffuse subset is predominant in pediatric patients (90%).

Purpose of the Study:

  • To compare the characteristics of juvenile systemic sclerosis with adult-onset systemic sclerosis.
  • To highlight differences in organ involvement, disease subset prevalence, and antibody profiles.
  • To analyze survival rates and disease progression in pediatric patients.

Main Methods:

  • Retrospective analysis of pediatric systemic sclerosis patient data.
  • Comparison of juvenile cohort data with established adult systemic sclerosis cohorts.
  • Review of organ involvement, subset classification, and serological markers.

Main Results:

  • Pediatric patients exhibit different organ involvement patterns compared to adults.
  • Survival rates are significantly better in juvenile systemic sclerosis.
  • Disease subset distribution shifts from predominantly diffuse in childhood to less diffuse in adulthood.
  • Pediatric-onset patients show a higher prevalence of overlap features and lower rates of anticentromere antibodies.

Conclusions:

  • Juvenile systemic sclerosis is a distinct entity with unique clinical and immunological characteristics.
  • Early diagnosis and understanding of these differences are crucial for effective management.
  • Long-term follow-up is essential as disease characteristics evolve into adulthood.